I find the fact that there are several compounds (peptide/nonpeptide antagonists, RNAi, or anti-CXCR4 mAb*) targeted to block the SDF-1/CXCR4 complex in clinical trials good for BLRX in the sense of validating the MOA.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.